Sigma Planning Corp’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.07M Buy
210,735
+39,162
+23% +$1.02M 0.13% 171
2026
Q1
$4.82M Buy
171,573
+5,500
+3% +$146K 0.13% 161
2025
Q4
$4.14M Buy
166,073
+9,868
+6% +$249K 0.11% 181
2025
Q3
$3.98M Sell
156,205
-9,720
-6% -$240K 0.11% 186
2025
Q2
$4.02M Sell
165,925
-14,167
-8% -$330K 0.12% 174
2025
Q1
$4.56M Buy
180,092
+28,562
+19% +$747K 0.15% 141
2024
Q4
$4.02M Sell
151,530
-16,023
-10% -$435K 0.13% 166
2024
Q3
$4.85M Buy
167,553
+165
+0.1% +$4.81K 0.15% 131
2024
Q2
$4.68M Buy
167,388
+1,878
+1% +$51.7K 0.15% 132
2024
Q1
$4.59M Buy
165,510
+83,668
+102% +$2.32M 0.14% 141
2023
Q4
$2.36M Sell
81,842
-90,871
-53% -$2.75M 0.18% 105
2023
Q3
$5.73M Buy
172,713
+7,558
+5% +$267K 0.21% 87
2023
Q2
$6.06M Sell
165,155
-29,477
-15% -$1.15M 0.22% 89
2023
Q1
$7.94M Sell
194,632
-24,759
-11% -$1.07M 0.26% 79
2022
Q4
$11.2M Sell
219,391
-2,134
-1% -$102K 0.4% 45
2022
Q3
$9.69M Sell
221,525
-2,180
-1% -$106K 0.37% 50
2022
Q2
$11.7M Sell
223,705
-3,753
-2% -$191K 0.41% 42
2022
Q1
$11.8M Sell
227,458
-27,738
-11% -$1.44M 0.35% 50
2021
Q4
$15.1M Sell
255,196
-3,991
-2% -$198K 0.42% 38
2021
Q3
$11.1M Buy
259,187
+10,907
+4% +$483K 0.34% 51
2021
Q2
$9.72M Sell
248,280
-2,240
-0.9% -$87.1K 0.29% 64
2021
Q1
$9.08M Sell
250,520
-422
-0.2% -$15K 0.29% 68
2020
Q4
$9.24M Buy
250,942
+20,151
+9% +$739K 0.31% 66
2020
Q3
$8.04M Buy
230,791
+29,075
+14% +$1.02M 0.32% 59
2020
Q2
$6.26M Buy
201,716
+18,871
+10% +$641K 0.27% 71
2020
Q1
$5.66M Buy
182,845
+6,582
+4% +$224K 0.34% 54
2019
Q4
$6.55M Buy
176,263
+8,757
+5% +$312K 0.28% 68
2019
Q3
$5.71M Buy
167,506
+21,534
+15% +$783K 0.27% 69
2019
Q2
$6M Sell
145,972
-2,129
-1% -$84.5K 0.31% 64
2019
Q1
$5.97M Buy
148,101
+3,257
+2% +$130K 0.34% 61
2018
Q4
$6M Sell
144,844
-4,630
-3% -$192K 0.44% 51
2018
Q3
$6.25M Sell
149,474
-279
-0.2% -$10.7K 0.37% 53
2018
Q2
$5.16M Buy
149,753
+5,740
+4% +$196K 0.35% 61
2018
Q1
$4.85M Buy
144,013
+5,081
+4% +$175K 0.35% 61
2017
Q4
$4.77M Buy
138,932
+3,712
+3% +$127K 0.37% 54
2017
Q3
$4.58M Sell
135,220
-5,969
-4% -$192K 0.38% 51
2017
Q2
$4.5M Sell
141,189
-23,528
-14% -$742K 0.42% 49
2017
Q1
$5.35M Buy
164,717
+36,064
+28% +$1.14M 0.52% 40
2016
Q4
$3.96M Buy
128,653
+17,527
+16% +$535K 0.43% 46
2016
Q3
$3.57M Buy
111,126
+9,939
+10% +$332K 0.42% 48
2016
Q2
$3.38M Buy
101,187
+7,904
+8% +$252K 0.44% 44
2016
Q1
$2.62M Buy
93,283
+8,402
+10% +$240K 0.36% 59
2015
Q4
$2.6M Buy
84,881
+2,446
+3% +$76.9K 0.36% 55
2015
Q3
$2.46M Buy
82,435
+11,316
+16% +$363K 0.39% 55
2015
Q2
$2.26M Sell
71,119
-3,631
-5% -$118K 0.31% 77
2015
Q1
$2.47M Sell
74,750
-6,089
-8% -$194K 0.33% 62
2014
Q4
$2.39M Buy
+80,839
New +$2.32M 0.32% 79

Other funds holding PFE

Sigma Planning Corp's PFE Position: Q2 2026 in Review

Sigma Planning Corp increased its Pfizer (PFE) stake by 23% in Q2 2026, buying an estimated $1.02M and bringing the position to 210,735 shares worth $5.07M. The position accounts for 0.13% of the portfolio, ranked #171.

Sigma Planning Corp first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $15.1M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Sigma Planning Corp held 210,735 shares of Pfizer worth $5.07M as of Q2 2026.
  • Sigma Planning Corp bought 39,162 Pfizer shares in Q2 2026, an estimated $1.02M.
  • Pfizer made up 0.13% of Sigma Planning Corp's portfolio in Q2 2026, its #171 holding.
  • Sigma Planning Corp first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
  • Sigma Planning Corp's Pfizer position peaked at $15.1M in Q4 2021.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.